CEL-SCI shares are trading higher after the company announced results from a bias analysis conducted for its concluded Phase 3 study of Multikine. Multikine cut the 5-year risk of death by half compared to control in its target population.
Portfolio Pulse from Benzinga Newsdesk
CEL-SCI shares are trading higher following the announcement of positive results from a bias analysis of its Phase 3 study of Multikine, which showed a significant reduction in the 5-year risk of death in its target population.
July 26, 2024 | 12:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CEL-SCI shares are trading higher after the company announced that its Phase 3 study of Multikine significantly reduced the 5-year risk of death in its target population.
The positive results from the Phase 3 study of Multikine are likely to boost investor confidence and drive the stock price higher in the short term. The significant reduction in the 5-year risk of death is a strong indicator of the drug's efficacy, which is critical for future approvals and market potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100